Medicare Patient Access and Practice Stabilization Act of 2025 This bill increases certain payment adjustments under the Medicare physician fee schedule for services furnished between April 1, 2025, and January 1, 2026.
Maddy summaryHR 833 creates a federal tax credit for individuals and corporations that contribute to scholarship granting organizations (SGOs) providing scholarships for elementary and secondary education. The credit allows taxpayers to deduct up to 10% of their adjusted gross income or $5,000 (whichever is less) for contributions to SGOs serving students from households with income up to 300% of the area median income. The bill establishes a $10 billion annual cap on the tax credit program, requires SGOs to verify student eligibility and maintain separate accounts, and prohibits government control over SGOs or private schools. It ensures scholarships can be used at public, private, or religious schools without discrimination based on religious character. The tax credit would be available for contributions made after December 31, 2025, with annual volume cap increases based on usage.
Maddy summaryThe Build the Wall Act of 2025 creates a new fund called the Southern Border Wall Construction Fund to finance physical barriers along the U.S. southern border. It requires all unspent funds from the Coronavirus State and Local Fiscal Recovery Funds (originally for pandemic relief) to be transferred immediately into this new account. The Secretary of Homeland Security would then use these redirected funds to construct and maintain border barriers. This bill changes how existing federal funds are allocated, shifting resources from pandemic recovery efforts to border security infrastructure.
Maddy summaryThis bill increases criminal penalties for individuals who re-enter the U.S. after being deported, removed, or excluded. It sets a maximum 5-year prison sentence for most cases, but adds up to 10 years for those with prior drug/crime convictions or multiple prior removals. For serious cases - such as aggravated felonies or two prior reentry convictions - it mandates a 5-20 year prison term. The law directly affects people who return without authorization after formal immigration removal proceedings.
Maddy summaryHJRES 30 is a congressional resolution seeking to block an Environmental Protection Agency (EPA) rule that implements the American Innovation and Manufacturing (AIM) Act of 2020. The resolution targets the EPA's specific rule (published in the Federal Register on October 11, 2024) which establishes a phasedown schedule for hydrofluorocarbons (HFCs) used in refrigeration, air conditioning, and other applications. If approved, this resolution would formally disapprove the EPA rule under the Congressional Review Act, preventing it from taking effect and halting the agency's implementation of the HFC phase-down. The resolution directly affects the EPA’s regulatory authority and the timeline for reducing HFC use, which impacts industries relying on these chemicals.
Life at Conception Act This bill declares that the right to life guaranteed by the Constitution is vested in each human being at all stages of life, including the moment of fertilization, cloning, or other moment at which an individual comes into being. Nothing in this bill shall be construed to authorize the prosecution of any woman for the death of her unborn child.
Maddy summaryHR 21, the Born-Alive Abortion Survivors Protection Act, requires medical staff at abortion facilities to provide the same immediate care and hospital admission to any infant born alive during an abortion as they would for any newborn. It mandates reporting failures to provide this care to law enforcement and imposes penalties of up to 5 years in prison for violations, with harsher penalties for intentional killing. The bill also allows women who undergo abortions to sue for civil damages, including triple the abortion cost, and provides for attorney fees. It defines "abortion" to exclude procedures performed after viability to preserve a live birth. This law directly affects healthcare providers at abortion facilities and creates new federal legal obligations for them.
Maddy summaryHR 643, the Federal Insurance Office Elimination Act, eliminates the Federal Insurance Office within the Treasury Department and removes the position of its Director. The bill updates federal law by deleting references to the office from the Dodd-Frank Act and other legislation, while clarifying that Treasury retains all existing authority over insurance matters. This change directly affects the structure of federal financial regulation by removing a specific oversight role and modifying related statutory language. The bill does not alter insurance policy or create new regulatory requirements, only removing an existing office and its associated references.
Maddy summaryHR 679 nullifies specific changes the Food and Drug Administration (FDA) made in January 2023 to the safety rules (REMS) for the abortion pill mifepristone. The bill prohibits the FDA from implementing any future safety rules for mifepristone that are substantially similar to the nullified changes. This directly affects the FDA's regulatory authority over mifepristone, which could impact how healthcare providers prescribe the medication and how patients access it. The bill focuses solely on reversing the FDA's 2023 modifications without altering the drug's broader approval status.
Maddy summaryHR 685, the SAVE Moms and Babies Act of 2025, prohibits the FDA from approving new abortion drugs or allowing investigational use of existing ones. It restricts existing abortion drugs to in-person administration by certified healthcare providers in clinics or hospitals (not pharmacies), limits use to pregnancies under 70 days gestation, and requires providers to certify they can handle complications like severe bleeding or ectopic pregnancies. The bill mandates reporting of adverse events (such as hospitalizations or infections) to the FDA without patient identifiers and defines "abortion drug" broadly as any drug intended to terminate pregnancy, excluding specific medical exceptions. This directly affects FDA approval processes, healthcare providers prescribing these drugs, and drug manufacturers.
